Shamburg News · 8-K filed Nov 13, 2026, 5:00 PM EST

NeOnc CEO Heshmatpour Buys 80,000 Shares; FDA Grants Type B End-of-Phase Meeting for NEO100

NTHI · NEONC TECHNOLOGIES HOLDINGS, INC.

  • Other event
  • Other
  • Materiality: low

NeOnc Technologies Holdings, Inc. announced on November 10, 2026 that Executive Chairman, President and CEO Amir F. Heshmatpour purchased 80,000 shares of common stock in open-market transactions on November 5, 6 and 9, 2026. On November 11, 2026, the Company announced that the U.S. Food and Drug Administration granted a Type B End-of-Phase meeting to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma, scheduled for early January 2027. Both press releases were furnished under Item 7.01 as Exhibits 99.1 and 99.2 and are not deemed filed.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001829126-26-012414.

Written from the filing by Shamburg Markets. Figures are as reported by the company.